InProTher
Copenhagen
About InProTher
InProTher is an immunotherapy company dedicated to developing the world’s first adaptive immune therapy capable of targeting immunosuppressive genes of ancient retroviruses.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $9.4M
- Funding stage: Seed
- Last round: Seed (May 2023)
- Website: inprother.com
- Phone: +4551756283
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/inprother-86658 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.